BREAKTHROUGH SLEEP APNEA TREATMENT
First FDA-Approved Medication for OSA in Adults with Obesity
Struggling with CPAP? Zepbound (tirzepatide) offers a revolutionary alternative for moderate-to-severe obstructive sleep apnea.
- Innovative: The first FDA-approved drug specifically for sleep apnea in adults with obesity
- Effective: Injectable medication that facilitates weight loss, directly addressing a root cause of OSA
- Comprehensive: Works alongside lifestyle modifications for optimal results
Chicago ENT is among the first providers offering this groundbreaking treatment to qualified patients.
Don’t let sleep apnea control another night of your life.
Schedule Your Consultation TodayZepbound is a newly approved treatment for moderate-to-severe obstructive sleep apnea (OSA). Zepbound is an injectable prescription medication that facilitates weight loss, thereby reducing obstructive sleep apnea. The medication works alongside a reduced-calorie diet and increased physical activity for optimal results.
Chicago ENT is pleased to offer Zepbound as a treatment option for qualified patients with OSA and obesity. This medication represents the first FDA-approved drug treatment specifically for obstructive sleep apnea in adults with obesity, marking a major advancement in sleep apnea care.
If you’ve struggled with other sleep apnea treatments or if obesity is contributing to your condition, schedule an appointment with us at Chicago ENT.
